About Checkpoint Therapeutics
Checkpoint Therapeutics is a company based in New York (United States) founded in 2014 was acquired by Sun Pharma in March 2025. It operates as a HealthTech. Checkpoint Therapeutics has raised $58 million across 1 funding round from investors including Sun Pharma. The company has 24 employees as of December 31, 2022. Checkpoint Therapeutics offers products and services including UNLOXCYT™. Checkpoint Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
- Headquarter New York, United States
- Employees 24 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Checkpoint Therapeutics, Inc.
-
Annual Revenue
$41 K (USD)-60as on Dec 31, 2024
-
Net Profit
-$56.24 M (USD)-8as on Dec 31, 2024
-
EBITDA
-$56.17 M (USD)-8as on Dec 31, 2024
-
Total Equity Funding
$58 M (USD)
in 1 rounds
-
Latest Funding Round
$58 M (USD), Series C
Dec 21, 2015
- Investors
-
Employee Count
24
as on Dec 31, 2022
-
Acquired by
Sun Pharma
(Mar 09, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Checkpoint Therapeutics
Checkpoint Therapeutics offers a comprehensive portfolio of products and services, including UNLOXCYT™.
UNLOXCYT™ is developed as a therapeutic drug candidate.
People of Checkpoint Therapeutics
Unlock access to complete
Funding Insights of Checkpoint Therapeutics
Checkpoint Therapeutics has successfully raised a total of $58M through 1 strategic funding round. The most recent funding activity was a Series C round of $58 million completed in December 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Checkpoint Therapeutics
Checkpoint Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sun Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Specialty generic pharmaceuticals and APIs are manufactured and marketed.
|
Locked | Locked | Locked |
Investor details for Checkpoint Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Checkpoint Therapeutics
Investment portfolio details for Checkpoint Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Checkpoint Therapeutics
Detailed financials for Checkpoint Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Checkpoint Therapeutics Comparisons
Peer comparison for Checkpoint Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Checkpoint Therapeutics
Checkpoint Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Revolution Medicines, Blueprint Medicines, Syndax and C4 Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Selective kinase inhibitors are developed for genomically defined cancers.
|
|
| Locked | Locked | Locked |
Targeted therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
Detailed competitors of Checkpoint Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Checkpoint Therapeutics
Complete news archive for Checkpoint Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Checkpoint Therapeutics
Checkpoint Therapeutics was founded in 2014 and raised its 1st funding round 1 year after it was founded.
Checkpoint Therapeutics is headquartered in New York, United States. It is registered at New York, New York, United States.
Checkpoint Therapeutics is a funded company, having raised a total of $58M across 1 funding round to date.
As of Dec 31, 2022, the latest employee count at Checkpoint Therapeutics is 24.
Annual revenue of Checkpoint Therapeutics is $41K as on Dec 31, 2024.
Checkpoint Therapeutics, Inc. is engaged in the development of innovative therapeutic drug candidates, including UNLOXCYT. The company operates within the biotechnology sector, focusing on advancing various candidates through different stages of development. Their work is supported by publications and presentations that highlight research progress. Recently acquired by Sun Pharma, Checkpoint Therapeutics continues to contribute to healthcare solutions.
Checkpoint Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and argenx.
Checkpoint Therapeutics offers UNLOXCYT™.
Checkpoint Therapeutics has 1 investor. Key investors include Sun Pharma.